157 related articles for article (PubMed ID: 2426823)
21. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
Collinson RJ; Wilson L; Boey D; Ng ZY; Mirzai B; Chuah HS; Howman R; Grove CS; Malherbe JAJ; Leahy MF; Linden MD; Fuller KA; Erber WN; Guo BB
Platelets; 2024 Dec; 35(1):2304173. PubMed ID: 38303515
[TBL] [Abstract][Full Text] [Related]
22. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and management of myeloproliferative disorders.
Laszlo J; Huang AT
Curr Probl Cancer; 1977 Jul; 2(1):1-42. PubMed ID: 268266
[No Abstract] [Full Text] [Related]
24. [MYELOPROLIFERATIVE SYNDROMES].
PIRESWDA F
Folha Med; 1964 Apr; 48():195-201. PubMed ID: 14271209
[No Abstract] [Full Text] [Related]
25. [Clinical conference: Histaaminemia in myeloproliferative syndromes].
Cadiou M; Ruff F; Meunier F; Attalah N; Bernadou A; Zittoun R; Parrot JL; Bousser J
Nouv Rev Fr Hematol; 1975; 15(2):261-9. PubMed ID: 126436
[No Abstract] [Full Text] [Related]
26. Myelofibrosis and acute megakaryoblastic leukemia in a child: topographic relationship between fibroblasts and megakaryocytes with an alpha-granule defect.
Breton-Gorius J; Bizet M; Reyes F; Dupuy E; Mear C; Vannier JP; Tron P
Leuk Res; 1982; 6(1):97-110. PubMed ID: 6461801
[TBL] [Abstract][Full Text] [Related]
27. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
Boiocchi L; Vener C; Savi F; Bonoldi E; Moro A; Fracchiolla NS; Iurlo A; Deliliers GL; Coggi G; Bosari S; Gianelli U
J Clin Pathol; 2011 Mar; 64(3):226-31. PubMed ID: 21217153
[TBL] [Abstract][Full Text] [Related]
29. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
30. Release of beta-thromboglobulin during storage of platelet concentrates.
Snyder EL
Vox Sang; 1981; 40 Suppl 1():115-6. PubMed ID: 6170171
[No Abstract] [Full Text] [Related]
31. The Role of β-Catenin in Bcr/Abl Negative Myeloproliferative Neoplasms: An Immunohistochemical Study.
Geduk A; Atesoglu EB; Tarkun P; Mehtap O; Hacihanefioglu A; Demirsoy ET; Baydemir C
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):785-9. PubMed ID: 26422250
[TBL] [Abstract][Full Text] [Related]
32. Classification of myeloproliferative disorders by bone marrow histology.
Frisch B; Bartl R; Burkhardt R; Jäger K; Mahl G; Kettner G
Bibl Haematol; 1984; (50):57-80. PubMed ID: 6590039
[No Abstract] [Full Text] [Related]
33. Platelet function and arachidonate metabolism in patients with myeloproliferative disorders.
Okuma M
Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1139-44. PubMed ID: 6800179
[No Abstract] [Full Text] [Related]
34. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
35. Release of beta-thromboglobulin during the preparation, in vitro storage and cryopreservation of platelet concentrates.
Taylor MA
J Clin Pathol; 1983 Jul; 36(7):811-5. PubMed ID: 6190844
[TBL] [Abstract][Full Text] [Related]
36. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
Nagao T; Yonekura S
Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
[No Abstract] [Full Text] [Related]
37. [TREATMENT OF HEMORRHAGIC THROMBOCYTHEMIA WITH RADIOPHOSPHORUS].
NAGY G
Magy Radiol; 1963 Nov; 15():345-50. PubMed ID: 14097642
[No Abstract] [Full Text] [Related]
38. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative diseases.
Thiele J; Holgado S; Choritz H; Georgii A
Scand J Haematol; 1983 Oct; 31(4):329-41. PubMed ID: 6578591
[TBL] [Abstract][Full Text] [Related]
39. Serum beta-2-microglobulin in disorders of myeloid proliferation.
Norfolk DR; Child JA; Roberts BE; Forbes MA; Cooper EH
Acta Haematol; 1983; 69(6):361-8. PubMed ID: 6190339
[TBL] [Abstract][Full Text] [Related]
40. [HEMORRHAGIC THROMBOCYTHEMIA AND THE "MYELOPROLIFERATIVE SYNDROME"].
VON KNORRING
Nord Med; 1964 Dec; 72():1443-6. PubMed ID: 14211013
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
